Accutar Biotech Inc., a biotechnology company specializing in artificial intelligence (AI) – empowered drug discovery, today announced that Dr. Erika Hamilton, director of breast cancer research at Sarah Cannon Research Institute (SCRI), has joined the Scientific Advisory Board (“SAB”) of the company to advise on clinical trials of the company’s phase 1 breast cancer programs that are orally bioavailable, chimeric degrader molecules designed to target and degrade ERα protein with high potency and selectivity.

Dr. Hamilton is a leader in the field of both breast and gynecologic cancers.  She had led numerous clinical trials, ranging from first-in-human phase I developmental trials to Phase III registrational trials.  Her expertise led to her appointment as the chairperson of the ASCO Scientific Committee for Metastatic Breast Cancer, which is just one of her many recognitions and accomplishments.  “We are honored to have Dr. Hamilton join our SAB at this critical inflection point for our company”, said Jie Fan, PhD, founder and CEO of Accutar.  “Her innovative contributions to drug development, focus on advancing new therapies, and compassion for patients makes her the ideal person to help forge the next steps to bring our revolutionary medicine to patients.”